Compare DAKT & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAKT | QURE |
|---|---|---|
| Founded | 1968 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.1M | 1.9B |
| IPO Year | 1994 | 2007 |
| Metric | DAKT | QURE |
|---|---|---|
| Price | $18.90 | $19.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $26.00 | ★ $58.55 |
| AVG Volume (30 Days) | 395.9K | ★ 2.4M |
| Earning Date | 12-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $770,283,000.00 | $15,751,000.00 |
| Revenue This Year | $12.94 | N/A |
| Revenue Next Year | $7.16 | $158.05 |
| P/E Ratio | $128.40 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.24 | $7.76 |
| 52 Week High | $24.38 | $71.50 |
| Indicator | DAKT | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 25.66 |
| Support Level | $17.09 | $20.55 |
| Resistance Level | $21.28 | $28.50 |
| Average True Range (ATR) | 0.87 | 1.47 |
| MACD | 0.23 | 0.12 |
| Stochastic Oscillator | 44.13 | 4.43 |
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.